Shorla Oncology Announces U.S. FDA Approval of Nelarabine Injection for the Treatment of T-cell Leukemia

Article

Nelarabine Injection ensures access to a lifesaving treatment, particularly for children, that historically has been in shortage.

Shorla Oncology (‘Shorla’), a US-Ireland pharmaceutical company, announced that the FDA approved the company’s oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL). In preparation for the immediate commercial launch of Nelarabine Injection, Shorla is working with its commercialization services partner, EVERSANA®, which it announced August 2021.

Nelarabine Injection provides patients with an alternative to a product that has historically been in shortage. This marks the first product approved in the US market for Shorla.

Shorla specializes in developing innovative oncology drugs, with a focus on orphan and pediatric cancers. With strong support from scientists and clinicians, the company has an advanced pipeline of oncology therapies to treat a number of unmet patient needs.

Sharon Cunningham, CEO and Co-founder of Shorla Oncology, said: “Nelarabine Injection is a critical treatment for patients living with T-cell Leukemia, particularly for children with leukemia, and it is our hope that today’s approval addresses the clinical need in this patient community.”

Recent Videos
Ted Sweetser
Ted Sweetser
Ted Sweetser
Amy Hessels, Bayer
Related Content